Latest Content

As utilization of GLP-1s grows for diabetes and weight management, out-of-pocket expenses and affordability concerns may affect broader health care policy discussions.

A session at CROI 2026 opened with questions on how glucagon-like peptide-1 receptor agonists could be used in HIV.

Data from the phase 3 BREAKWATER trial supported full FDA approval of the encorafenib combination for metastatic CRC with a BRAF V600E mutation, demonstrating significant survival gains.

Patients with ocular myasthenia gravis (MG) should be regularly assessed to reduce the chances of progression to generalized MG.

Bruton tyrosine kinase–based therapies show promising but variable efficacy in Richter transformation, current data suggest.

The approval, dupilumab's ninth in the US, is supported by the phase 3 LIBERTY-AFRS-AIMS trial.

New research shows that adherence to antiretroviral therapy and pre-exposure prophylaxis depends on a steady budget through PEPFAR and SNAP.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

The authors discuss ways to ensure that accountable care organizations do not bear the cost of inaccurate spending growth predictions.